Boulos Haraoui
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
Rubbert-Roth A, Kato K, Haraoui B, Rischmueller M, Liu Y, Khan N, Camp H, Xavier R. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study. Rheumatol Ther 2024; 11:1197-1215.
Jul 20, 2024Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
Jul 20, 2024Rheumatol Ther 2024; 11:1197-1215
Rubbert-Roth Andrea, Kato Koji, Haraoui Boulos, Rischmueller Maureen, Liu Yanxi, Khan Nasser, Camp Heidi S, Xavier Ricardo M
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Rubbert-Roth A, Enejosa J, Pangan A, Haraoui B, Rischmueller M, Khan N, Zhang Y, Martin N, Xavier R. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med 2020; 383:1511-1521.
Jan 15, 2020Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Jan 15, 2020N Engl J Med 2020; 383:1511-1521
Rubbert-Roth Andrea, Enejosa Jeffrey, Pangan Aileen L, Haraoui Boulos, Rischmueller Maureen, Khan Nasser, Zhang Ying, Martin Naomi, Xavier Ricardo M